**Begg 1982** Begg, E., Chinwah, P., Webb, C., Day, R. & Wade, D. Enhanced metabolism of mexiletine after phenytoin administration. *British Journal of Clinical Pharmacology* **14**, 219–223 (1982).

**Campbell 1978 ** Campbell NP, Kelly JG, Adgey AA, Shanks RG. Mexiletine in normal volunteers. *Br J Clin Pharmacol*. 1978;6(4):372-373.

**DrugBank DB00379** (https://www.drugbank.ca/drugs/DB00379)

**Joeres 1987** Joeres, R., Klinker, H., Heusler, H., Epping, J., Richter, E. (1987). Influence of mexiletine on caffeine elimination*. Pharmacology & therapeutics*, 33(1), 163-169.

**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531.

**Kusumoto 1998 ** Kusumoto M, Ueno K, Tanaka K, et al. Lack of pharmacokinetic interaction between mexiletine and omeprazole. *Ann Pharmacother*. 1998;32(2):182-184. 

**Labbé 2000** Labbé L, O’Hara G, Lefebvre M, et al. Pharmacokinetic and pharmacodynamic interaction be mexiletine and propafenone in human beings. *Clin Pharmacol Ther*. 2000;68(1):44-57.

**Mexiletine, Drugs.com** Mexiletine, Drugs.com, Website drugs.com/pro/mexiletine.html

**Pentikäinen 1984** Pentikainen P, Halinen M, Helin M. Pharmacokinetics of intravenous Mexiletine in patients with acute myocardial infarction. *J Cardiovasc Pharmacol*. 1984;6:1-6.

**PK-Sim Ontogeny Database Version 7.3** (https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf)

**Pringle 1986** Pringle T, Fox J, McNeill J, et al. Dose independent pharmacokinetics of mexiletine in healthy volunteers. *Br J Clin Pharmacol*. 1986;21(3):319-321.

**SmPC Namuscla** SmPC Namuscla 167 mg hard capsules, 2019, website medicines.org.uk/emc/product/9838/smpc

**Begg 1982** Webb C, Day R, Chinwah P, Wade D, Begg E. Enhanced metabolism of mexiletine after phenytoin administration. *Br J Clin Pharmacol*. 2012;14(2):219-223. 

**Wei 1991** Wei X, Dai R, Zhai S, Thummel KE, Friedman FK, Vestal RE. Inhibition of human liver cytochrome P-450 1A2 by the class IB antiarrhythmics mexiletine, lidocaine, and tocainide. *J Pharmacol Exp Ther*. 1999;289(2):853-858.

**Willmann 2007** Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. *J Pharmacokinet Pharmacodyn* 2007, 34(3): 401-431.